AGLYC, de GlyCardial

The First In Vitro Diagnostic Device for the Early Detection of Cardiac Ischemia

Cardiovascular diseases (CVD) are the leading cause of death across the globe, accounting for 31% of all deaths in 2015. Early detection of ischemia (restriction in blood supply to tissues, causing oxygen shortage) is essential to prevent the progression of heart damage, but for the moment there are no biomarkers for the early detection of cardiac ischemia. In fact, almost 90% of the available in vitro diagnostic (IVD) methods are based on the quantification of markers of necrosis, an advanced stage of organ damage. Obviously, these methods are useless for the early detection of ischemic damage.

Our client, GlyCardial Diagnostics SL, has developed <strong>AGLYC</strong>, an IVD device based on the rapid quantification of the plasmatic levels of Apo J-Glyc in plasma as a novel biomarker for the diagnosis, prognosis and risk stratification of ischemia and ischemic tissue damage.

GlyCardial is composed of four people, three of them women, and focused on the development of this important project.

AGLYC’s main mission is to reduce the impact of the disease on patients’ lives, improving the early diagnosis of cardiac ischemic events.

To carry out its project, GlyCardial applied to the May 2018 call of phase 1 of the SME Instrument. After winning funding at the first attempt, they applied to the October 2018 call of phase 2, passed to the interview phase and we are pleased to announce that they also won the necessary grant to carry out this project, obtaining a score of 13.99.

We are very pleased with our participation in the record success of GlyCardial: having secured funding for Phase 1 and Phase 2 within the same year and on the first attempt. We wish them many successes in the development of this fantastic project that will save the lives of so many people!